Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (10)
Poster categories
  • Thematic Poster Session (11)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • x TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • TPS33 (12)
  • TPS34 (10)
  • TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • TPS66 (7)
  • TPS67 (10)
  • x TPS68 (5)
  • TPS69 (11)
  • TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • x TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • TPS91 (3)
22 results
Thumbnail

- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests

Thumbnail

- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom

Thumbnail

- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)

Thumbnail

- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center

Thumbnail

- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom

Thumbnail

- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data

Thumbnail

- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy

Thumbnail

- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review

Thumbnail

- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase

Thumbnail

- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy

Thumbnail

D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas

Thumbnail

- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis

Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Thumbnail

D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor

Thumbnail

D3.155 - Th2–Th17 immune shift following dupilumab therapy

Thumbnail

D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry

Thumbnail

D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM